For many patients with peritoneal malignancies, a clinical trial is not just research; it is a real treatment opportunity when standard options have been exhausted. The PSOGI 2025 Manifesto denounces the fact that participation in these studies is profoundly unequal. At Viamed, we work to ensure that innovation reaches those who need it most, breaking down the barriers between the laboratory and the patient’s bedside.
Research as a Driver of Hope
Clinical trials provide access to drugs and surgical techniques that are not yet widely available. However, access is often a privilege for a few due to a lack of information and coordination.
Current Challenges: Why Doesn’t Innovation Reach Everyone?
The Barcelona Manifesto focuses on the deficiencies that limit survival:
- Lack of Awareness and Delays: Many patients never learn that a trial exists for their specific tumor type, or they receive the information when the disease is too advanced.
- Lack of Connection: There is a disconnect between the centers where patients are diagnosed and the centers where research is conducted.
- Opacity in Registries: The absence of a centralized, easy-to-understand database makes searching for a trial an almost impossible task for a family.
- Exclusion Criteria: Sometimes, entry requirements for a study are so strict that they exclude patients who could benefit enormously.
IVOQA: Cutting-edge Specialization Under the Leadership of Dr. Delia Cortés Guiral
At IVOQA, we understand that research is an integral part of treatment. We don’t wait for the future to arrive; we help build it for our patients.
- Connection to the Scientific Network: Thanks to the international leadership of Dr. Delia Cortés Guiral, IVOQA is in constant contact with the leading peritoneal oncology research groups worldwide.
- Transparent Information: We advise our patients on national and international clinical trial options that best fit their molecular profile.
- Promoting Clinical Innovation: We don’t just follow protocols; we actively participate in improving techniques such as PIPAC and new HIPEC combinations, always seeking to expand curative options.
The future of peritoneal oncology is being written today in research centers. At IVOQA and Viamed, we are committed to making that future accessible to all our patients, without exception.
Do you want to know if there is an innovative option or clinical trial for your case? Consult with the IVOQA team and request a review of your clinical history with Dr. Delia Cortés Guiral.
